The spiked-in blood samples obtained were processed with the CellSearch® platform, undergoing an EPCAM-based enrichment step, followed by the evaluation of the enriched cells for the expression of CK (tumor identification marker), CD45 (negative selection marker) and HER2 (characterization marker). Here, ERBB2 is linked to neoplasm.